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PleaseMedical abortionOne study1 has reported that the rate of unintended or
incidental pregnancy in the United States declined sub-
stantially between 2008 and 2011, but unintended pregnancies
were most prevalent among women and girls who were poor or
women who were cohabiting. In the same study, the percent-
age of unintended pregnancies that ended in abortion remained
stable during this period (40% in 2008 and 42% in 2011);
however, the rate of unintended pregnancies that ended in birth
declined from 27/1000 in 2008 to 22/1000 in 2011 in women
and girls aged 15e44 years.1 However, unintended pregnancy
is still the major contributor to abortion.2
Since the 1960s, abortion through vacuum aspiration or
dilatation and curettage has been the method used to suc-
cessfully terminate an early pregnancy. The risks of surgery
and anesthesia for women undergoing an abortion, and the
shortage of providers that offer comprehensive abortion care
services are always concerning.3,4 A recent report from the
United States showed that approximately 16.1 million abortion
procedures were conducted from 1998 to 2010 and resulted in
the deaths of 108 women, which is an overall mortality rate of
0.7 deaths/100,000 procedures. The mortality rate per 100,000
procedures increased with gestational age from 0.3 deaths for
procedures performed at 8 gestational weeks to 6.7 for
procedures performed at 18 gestational weeks. It is impor-
tant to show that most abortion-related deaths at 13 gesta-
tional weeks were associated with anesthesia complications
and infection.5 All of these studies suggest that alternative
therapy is always welcome, including medical abortion, for
early pregnancy termination to minimize the need of more
invasive procedures such as surgery.6e9 The combination of
misoprostol, a prostaglandin analog that has a strong utero-
tonic effect, and mifepristone (RU-486, a selective progester-
one receptor modulator), creates a potent antiprogestogenic
effect for pregnancy. This treatment is used to block the pro-
gesterone receptors (PR) and glucosteroid receptors. It may
also sensitize the uterine myometrium to prostaglandins,
decrease the contractility threshold of the uterus, and ripen the
cervix, thereby facilitating abortion.6,9 This combination
treatment of misoprostol and mifepristone is more effective
than single agents9,10; therefore, Dr. Jiang's study in this issue
of the Journal of Chinese Medical Association also used the
combination therapy for medical abortion.x.doi.org/10.1016/j.jcma.2016.04.005
901/Copyright © 2016, the Chinese Medical Association. Published by El
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
cite this article in press as: Li Y-T, Medical abortion, Journal of the ChineJiang et al11 investigated 63 pregnant primiparous women,
aged 18e30 years with a gestational period of 35e49 days,
who visited the Second Affiliated Hospital of Wenzhou Medical
University (Zhejiang, China) between March 2009 and April
2011. The authors attempted to compare the expression of
estrogen receptors (ERs), PRs, insulin-growth factor-1 (IGF-1),
and vascular endothelial growth factor (VEGF) in the chorionic
villi between incomplete and complete abortions.11 Their study
showed no statistically significant difference in IGF-1 and
VEGF messenger RNA (mRNA) expression, although the
authors claimed that immunohistochemical staining of VEGF
and IGF-1 was relatively stronger in the incomplete abortion
group than in the complete abortion group, and achieved stat-
istical significance.11
However, there are many aspects of their study that remain
unclear, and thus are worthy of further discussion. First, their
study indicated that up to 54% (34/63) of pregnant women had
an incomplete medical abortion.11 This finding suggests that
the successful abortion rate in Jiang's report was very low. For
example, a study by Li et al6 enrolled 242 women with
unintended pregnancies of 49 days of gestational. After
treatment by medical abortion, the complete abortion rate was
92.6%.6 On comparing the results of the Li et al6 study and
Jiang et al's11 study, we found a significant difference,
including the prescription route and dosage of the drugs,
which was emphasized in our previous comment, after mod-
ifying the original description: “Overcoming the barriers of
treatmentda better route and a better outcome.”8 Dr Li used
200 mg mifepristone orally, followed by the immediate
intravaginal placement of 600 mg misoprostol6; Dr Jiang used
50 mg mifepristone orally, followed by 25 mg of oral mife-
pristone every 12 hours at home (for a total dose of 150 mg
mifepristone), and finally 600 mg oral misoprostol in the
management of the same criteria of a similar study pop-
ulation.11 This protocol contributed to successful abortion
rates of 92.6%6 and 54%.11 The sublingual and vaginal routes
of misoprostol administration resulted in a shorter abortion
duration, compared with the oral route.6 In addition, the vag-
inal administration of misoprostol (600 mg) appears to gen-
erate fewer adverse effects without interfering with the
efficacy of medical abortion for early pregnancy. Furthermore,
patient compliance may be questionable in Jiang's study. It issevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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clinician's recommendation to take the medication.
Second, the mean induction to abortion interval was
approximately 6 hours in Li's study,6 but the interval for col-
lection of a sample in Dr Jiang's study11 was only 4 hours.
Therefore, it is highly possible that the sample in Jiang's study
was not adequately collected, partly because of the need for a
longer duration to induce abortion and partly because of the
reduced amount or absence of chorionic villi collected in their
experimental protocol.11
Third, a significant discrepancy of data presented by
reverse transcriptase polymerase chain reaction (i.e., mRNA
expression) and immunohistochemical analysis (i.e., protein
expression) is noted in Jiang's study.11 The cause of this dis-
crepancy in the expression of mRNA level (factory) and pro-
tein level (product) was unknown, since Dr. Jiang's study
showed the down-regulated mRNA levels but increased
expression of protein levels (IGF-1 and VEGF). It is unusual,
because most studies often showed the similar trend for
increasing expression of both mRNA and protein or decreasing
expression of both.12,13 Are there any unknown truncated
forms of these targets? In fact, the typical example of a
truncated protein is p53, which is often an overexpression of a
function-lost protein when p53 genes are mutated.14 However,
in our limited knowledge, we did not find any truncated form
of either IGF-1 or VEGF.
It is noteworthy that women who want to avoid surgery
seem to value the option of a medical abortion and tend to be
satisfied, regardless of the regimen used.9 Dr Jiang's study
showed that more than one-half of the patients' pregnancies
were ended by an incomplete abortion.11 We believe that this
was also true in their study in which nearly one-half of the
patients were unsatisfied with their method.
Furthermore, what is the value of testing the expression of
IGF-1 and VEGF of chorionic villi? Could physicians reverse
or change the treatment strategy on knowing that a patient has
increased expression of IGF-1 or VEGF before prescribing or
performing this procedure? In fact, a clinician cannot perform
such a preabortion test because specimens would be needed to
test for the aforementioned genes, which requires a “proce-
dure” to obtain them. It is impossible to know the expression
of IGF-1 and VEGF in the chorionic villi before the induction
of a medical abortion. Therefore, we do not believe that the
authors could provide any new information to predict the
success of the inducing medical abortion by mifepristone and
misoprostol, even though the authors claimed this.11
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